This study will attempt to determine the efficacy of checkpoint inhibitor immunotherapy with nivolumab and ipilimumab combination therapy followed by nivolumab monotherapy in patients with metastatic prostate cancer harboring loss of CDK12 function.
This study investigates the efficacy of checkpoint inhibitor immunotherapy in patients with metastatic cancer with CDK12 mutations. The study includes two cohorts of patient groups: castration resistant metastatic prostate carcinoma and other solid tumor histologies. Both cohorts receive the same treatment with the combination of nivolumab and ipilimumab followed by nivolumab.